Zdrowie i gospodarka · 07/06/2019
FDA Announces Draft Guidance for Nonalcoholic Steatohepatitis Treatment
The FDA is releasing a draft guidance document outlining its recommendations for developing drugs to treat nonalcoholic steatohepatitis with compensated cirrhosis, focusing on phase 3 clinical trials.
Source: Federal Register — Food and Drug AdministrationOpen original release →